PT-141 Peptide (Bremelanotide): 10mg/ml Research Autoinjector Pen
Researching PT-141 (bremelanotide)? This guide explains what the melanocortin receptor agonist is, how it has been studied in research on sexual-response pathways in both men and women, how it differs from the approved drug product, and how PrymaLab supplies it — a preloaded 3ml autoinjector pen at 10mg/ml for in-vitro and non-human research only.
Research-use-only disclaimer: PT-141 supplied by PrymaLab is a research-use-only material for in-vitro and non-human laboratory study. It is not for human or veterinary use and is not approved by the FDA to diagnose, treat, cure, or prevent any condition. Always verify the legal status of research compounds in your jurisdiction.
Quick Answer
What is PT-141? PT-141, also called bremelanotide, is a synthetic peptide that acts as a melanocortin receptor agonist (notably at MC4R). In research it is studied for central nervous-system pathways involved in sexual response. PrymaLab supplies it as a research-use-only 3ml pen at 10mg/ml.
Important: bremelanotide is also the active ingredient in an FDA-approved prescription medicine for a specific human indication, but this PrymaLab product is a research-use-only material, not the approved drug, and is not for human use.
PT-141 (bremelanotide) is a melanocortin receptor agonist studied in research on central sexual-response pathways.
PrymaLab format: a preloaded 3ml autoinjector pen at 10mg/ml for reproducible, traceable measured delivery.
Studied in both men and women in the research literature, though mechanisms and findings differ by model and study.
Research-use-only. An approved bremelanotide medicine exists for a specific human indication, but this product is not that drug and is not for human use.
What Is PT-141 (Bremelanotide)?
PT-141, or bremelanotide, is a synthetic cyclic peptide that acts as a melanocortin receptor agonist. It is a metabolite of an earlier compound (melanotan II) and is studied primarily for its activity at the melanocortin-4 receptor (MC4R) in the central nervous system.
For a laboratory, what is PT-141 means a defined research compound supplied at a reference concentration for reproducible in-vitro and non-human studies. PrymaLab presents PT-141 at 10mg/ml in a sealed 3ml autoinjector pen.
How PT-141 Is Studied to Work
Unlike vascular-acting compounds, PT-141 is most often discussed in research as acting through central melanocortin pathways rather than directly on the vascular system. This central mechanism is the focus of much of the preclinical and clinical research literature on bremelanotide.
Why Researchers Choose the PrymaLab PT-141 Autoinjector Pen
PrymaLab supplies PT-141 in a preloaded 3ml autoinjector pen calibrated to 10mg/ml, giving laboratories a uniform, repeatable format for in-vitro and non-human research. The sealed pen supports clean handling, measured delivery, and clear record-keeping across replicates.
- Fixed 10mg/ml reference concentration for reproducible study design.
- Measured delivery for reproducible volumes and reduced variability.
- Optional glass reloading cylinder to standardize preparations between runs.
- Batch traceability linking every draw to a single reference batch.
PrymaLab PT-141 Specifications
| Specification | Detail |
|---|---|
| Compound | PT-141 (bremelanotide, melanocortin receptor agonist) |
| Form | Preloaded autoinjector pen (research-use-only) |
| Pen size | 3ml |
| Concentration | 10mg/ml |
| Optional accessory | Glass reloading cylinder for standardized refills |
| Intended use | In-vitro & non-human laboratory research only |
| Reference | PubChem compound record (Bremelanotide) |
How to Handle and Store the PT-141 Research Pen
Follow these laboratory handling steps when receiving and using the research-use-only PT-141 autoinjector pen. These describe lab handling only and are not human-use instructions.
- Receive and inspect. Confirm the PT-141 pen is sealed, the batch number is legible, and the solution is clear and free of particulates before logging it into inventory.
- Refrigerate and protect from light. Store the preloaded pen at 2-8°C away from light; avoid freeze-thaw cycles that can degrade bremelanotide.
- Record the batch. Log lot number, concentration (10mg/ml), and receipt date so each measured delivery traces to one reference batch.
- Dispense measured volumes. Use the pen’s measured-delivery mechanism to draw reproducible volumes into your in-vitro or non-human preparation, documenting each draw.
- Standardize with the reload cylinder. Where supplied, use the glass reloading cylinder to refill and keep the preparation consistent across replicates.
- Track stability and dispose. Record the open date, monitor working stability per protocol, and dispose of the research material via your laboratory chemical-waste process.
PT-141 in Research: Studies in Men and Women
Search terms like PT-141 for men and PT-141 for women reflect that bremelanotide has been investigated across sexes in the research literature. In preclinical and clinical studies, bremelanotide has been examined for central pathways related to sexual response. Findings, models, and endpoints differ between studies, and outcomes in research models should not be generalized.
Questions about PT-141 dosage in the literature refer to controlled study designs. PrymaLab supplies a 10mg/ml reference concentration to support reproducible research and does not provide human dosing guidance of any kind.
Research Material vs the Approved Bremelanotide Drug
This is an important distinction. Bremelanotide is the active ingredient in an FDA-approved prescription medicine for a specific human indication, administered under medical supervision. The PrymaLab product is a separate, research-use-only material.
| Attribute | PrymaLab PT-141 (this product) | Approved bremelanotide medicine |
|---|---|---|
| Category | Research-use-only material | FDA-approved prescription drug |
| Intended use | In-vitro & non-human research | Specific human indication, by prescription |
| Oversight | Researcher / laboratory | Licensed clinician + regulated pharmacy |
| Format here | 3ml pen, 10mg/ml | Manufacturer-specified drug product |
| Human use | Not for human use | Per clinician and label |
If your interest is therapeutic rather than research, the approved medicine must be obtained through a licensed clinician — not as a research compound.
PT-141 Side Effects & Legal Status in Research Settings
Information on PT-141 side effects in humans comes from the clinical literature on the approved drug, not from this research material. For the laboratory, the relevant considerations are correct handling, storage, and documentation. Confirm the legal status of bremelanotide research materials in your jurisdiction before purchase.
Reminder: PrymaLab PT-141 is sold strictly for in-vitro and non-human laboratory research. It is not the approved drug product, not a supplement, and must not be administered to humans or animals.
Need research-grade PT-141 at a defined concentration?
PrymaLab supplies PT-141 (bremelanotide) as a preloaded 3ml autoinjector pen at 10mg/ml, research-use-only, with transparent sourcing and batch traceability.
Frequently Asked Questions
What is PT-141?
PT-141 (bremelanotide) is a synthetic peptide that acts as a melanocortin receptor agonist, studied in research for central pathways related to sexual response. PrymaLab supplies it as a research-use-only 3ml autoinjector pen at 10mg/ml. It is not the approved drug product and is not for human use.
Is PT-141 studied for men or women?
Bremelanotide has been investigated in both men and women in the research literature, with studies focusing on central melanocortin pathways. Models and endpoints vary by study. PrymaLab PT-141 is a research material only and is not intended for human use by anyone.
What is the PT-141 dosage used in studies?
Published PT-141 dosage figures refer to controlled research or clinical study designs, not to this research material. PrymaLab supplies a 10mg/ml reference concentration for reproducible study and provides no human dosing guidance.
Does PT-141 have side effects?
Human side-effect data for bremelanotide comes from clinical studies of the approved drug, not from this research-use-only material. As a research compound, PrymaLab PT-141 should be handled only by qualified researchers under laboratory controls.
Is PT-141 a nasal spray or an injectable?
PT-141 is studied in multiple formats in the literature, including nasal and subcutaneous routes. PrymaLab supplies PT-141 as a preloaded liquid autoinjector pen (10mg/ml) for research handling — not as a nasal spray and not for human administration.
How is PrymaLab PT-141 different from the approved bremelanotide drug?
The approved bremelanotide medicine is an FDA-approved prescription drug for a specific human indication. PrymaLab PT-141 is a separate research-use-only material supplied at 10mg/ml for laboratory study, not for human use.
Where can researchers buy PT-141 for research?
Qualified researchers can obtain PT-141 for research-use-only directly from PrymaLab at prymalab.net, supplied in the preloaded 3ml autoinjector pen format at 10mg/ml.
References & Further Reading
- PubChem Compound Summary, Bremelanotide (PT-141). National Library of Medicine. pubchem.ncbi.nlm.nih.gov/compound/Bremelanotide.
- U.S. Food and Drug Administration. Bremelanotide (Vyleesi) prescribing information — approved-drug reference (human indication). FDA.gov.
- Kingsberg, S.A., et al. (2019). Bremelanotide for hypoactive sexual desire disorder: randomized clinical trials. Obstetrics & Gynecology, 134(5), 899–908.
- Molinoff, P.B., et al. (2003). PT-141: a melanocortin agonist for the treatment of sexual dysfunction. Annals of the New York Academy of Sciences, 994, 96–102.
- USP General Chapter <1225>. Validation of Compendial Procedures (HPLC purity-testing principles). United States Pharmacopeia.
Related research pages on PrymaLab: What is a peptide? · All research peptides
Final disclaimer: This product description is for educational and informational purposes only and is not medical advice. The compounds described by PrymaLab — including BPC-157, TB-500, NAD+, PT-141 (bremelanotide), Selank, and Semax — are sold strictly as research-use-only materials for in-vitro and non-human laboratory study. They are not approved by the FDA for human or veterinary therapeutic use, and statements about their effects have not been evaluated by the FDA. Nothing here is a recommendation to purchase, possess, or administer any compound to humans or animals.
Always consult a licensed professional and verify the legal status of any compound in your jurisdiction before purchase. PrymaLab supplies these materials for qualified researchers only and assumes no responsibility for misuse.
1 review for Preloaded Autoinjector | PT-141 | 3ml Pen | 10mg/ml